I-131-Apamistamab

N/A

Report date: 2025/09/11 14:20:58

Base Information

Drug NameI-131-Apamistamab
Drug Alias Nameiodine (131I) apamistamabIomab-ACT131I-ApamistamabI-131 apamistamabIomab-B +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive therapeutic agent +[5] 
Mechanisms of ActionAnti-CD45Ionising radiation emitters
TargetsLeukocyte common antigen
Therapy Area/IndicationsAngioimmunoblastic T-cell LymphomaGraft vs Host DiseasePancytopenia +[39] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesFred Hutchinson Cancer Research Center
China Registration ClassN/A

Develop Information

Active CompaniesUniversity of Texas Southwestern Medical CenterColumbia UniversityImmedica Pharma Ab +[4] 
Inactive CompaniesFred Hutchinson Cancer Research Center
Active IndicationsGraft vs Host DiseaseAnemia, Sickle CellLymphoma, Large B-Cell, Diffuse +[8] 
Inactive IndicationsAngioimmunoblastic T-cell LymphomaPancytopeniaMyelodysplastic Syndromes +[31] 

Other Information

ATC CodeN/A
Related LinksN/A